NURIX THERAPEUTICS, INC.
Last · NASDAQ$23.67+1.54 (+6.96%)close · yahoo · 15h ago
Market cap$2.59B109.2M sh
P/E · TTM9.7fwd -21.9 · eps 2.43
Beta1.82vs S&P 500
Div yield0.00%annual · TTM
52w range
$9.18$28.23
Volume3.0Msession
| Revenue | $688.4M |
|---|---|
| Operating income | $372.8M |
| Net income | $373.1M |
| Free cash flow | $442.8M |
| Operating margin | 54.2% |
| Net margin | 54.2% |
| Return on equity | 38.5% |
| Period | 2026 |
Loading chart…
Recent earnings
Reported · 2:00 AM UTC+2
Period
Sep 2026
EPS
$4.73Missed−7.44%
Est. revenue
81.3M
Reported · 2:00 AM UTC+2
Period
Aug 2026
EPS
$4.73Missed−7.5%
Est. revenue
—
Press & signals
- GlobeNewswire
Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer
- GlobeNewswire
Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer
- GlobeNewswire
Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
The rest of this company's wire — with summaries and source links — is part of Pro.
See plans